Trifluoperaizne (TFP) is an antipsychotic medication with limited oral bioavailability due to extensive first-pass metabolism; consequently, the goal of this project was to develop Leciplex nanoparticles to improve the bioavailability of TFP and to prolong its nasal residence time for treatment of the depression. Leciplex NPs were prepared using negatively charged phospholipid, cationic surfactant and biocompatible solvent and optimized using the 21 31 full factorial statistical design using various surfactants and different phospholipid to surfactant ratios. Design Expert® software was employed to select the optimum formula. The formulae were characterized regarding their particle size (PS), polydispersity index (PDI), zeta potential (ZP), entrapment efficiency percentages (EE %), amount of drug released after 6 hours (Q6h), transmission electron microscopy analysis, fourier transform infrared ray spectroscopy (FT-IR) and stability for six months. Optimized formula was contained dimethyldidodecylammonium bromide as surfactant and had a